Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Watch and Wait Strategy in LARC After Neoadjuvant Chemoradiotherapy
NCT04443543Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jun 2020
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of tislelizumab in rectal cancer (2 arms), sponsored by Fudan University. Primary endpoint: Clinical Complete Response Rate. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04443543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04443543.